Response to docetaxel/carboplatin in patients with hormone-refractory prostate cancer not responding to taxane-based chemotherapy.

Published

Journal Article

Few treatment options are available for patients with metastatic hormone-refractory prostate cancer (HRPC) that is not responsive to or continues to progress after taxane-based chemotherapy. Although single-agent carboplatin has modest activity in HRPC, carboplatin chemotherapy could induce a synergistic effect when combined with taxanes in patients with disease resistant to taxane-based chemotherapy. We report a case series of 4 consecutive patients treated with docetaxel (60-70 mg/m2) plus carboplatin (area under the curve of 4/5) following progression after taxane-based chemotherapy. Prostate-specific antigen levels decreased by > 50% in all 4 patients and were associated with improvement in symptoms in 3 of 4 patients. Treatment was well tolerated, with fatigue as the most common reported side effect. Patients received 4-11 cycles of treatment and, after initiation of docetaxel/carboplatin chemotherapy, survival ranged from 4.5 months to 12 months. In this small series, there is a suggestion of a greater than expected response with carboplatin and docetaxel for patients who exhibit disease progression despite taxane-based chemotherapy or do not respond to therapy. A clinical trial to evaluate this effect has been initiated.

Full Text

Duke Authors

Cited Authors

  • Oh, WK; George, DJ; Tay, MH

Published Date

  • June 2005

Published In

Volume / Issue

  • 4 / 1

Start / End Page

  • 61 - 64

PubMed ID

  • 15992464

Pubmed Central ID

  • 15992464

International Standard Serial Number (ISSN)

  • 1540-0352

Digital Object Identifier (DOI)

  • 10.3816/cgc.2005.n.014

Language

  • eng

Conference Location

  • United States